tbuckley/cabot-search huggingface dataset:
Growth Differentiation Factor–15 and Risk of CKD Progression
Authors: Viji Nair, Cassianne Robinson-Cohen, Michelle R. Smith, Keith A. Bellovich, Zeenat Yousuf Bhat, Maria Bobadilla, Frank Brosius, Ian H. de Boer, Laurent Essioux, Ivan Formentini, Crystal A. Gadegbeku, Debbie Gipson, Jennifer Hawkins, Jonathan Himmelfarb, Bryan Kestenbaum, Matthias Kretzler, Maria Chiara Magnone, Kalyani Perumal, Susan Steigerwalt, Wenjun Ju, Nisha Bansal
Journal: Journal of the American Society of Nephrology (2017)

Growth differentiation factor-15 (GDF-15) is a member of the TGF-β cytokine superfamily that is widely expressed and may be induced in response to tissue injury. Elevations in GDF-15 may identify a novel pathway involved in loss of kidney function among patients with CKD. Among participants in the Clinical Phenotyping and Resource Biobank (C-PROBE) study and the Seattle Kidney Study (SKS), we tested whether kidney tissue expression of GDF15 mRNA correlates with circulating levels of GDF-15 and whether elevations in circulating GDF-15 are associated with decline in kidney function. In matching samples of 24 patients with CKD from the C-PROBE study, circulating GDF-15 levels significantly correlated with intrarenal GDF15 transcript levels (r=0.54, P=0.01). Among the 224 C-PROBE and 297 SKS participants, 72 (32.1%) and 94 (32.0%) patients, respectively, reached a composite end point of 30% decline in eGFR or progression to ESRD over a median of 1.8 and 2.0 years of follow up, respectively. In multivariable models, after adjusting for potential confounders, every doubling of GDF-15 level associated with a 72% higher (95% confidence interval, 1.21 to 4.45; P=0.003) and 65% higher (95% confidence interval, 1.08 to 2.50; P=0.02) risk of progression of kidney disease in C-PROBE and SKS participants, respectively. These results show that circulating GDF-15 levels strongly correlated with intrarenal expression of GDF15 and significantly associated with increased risk of CKD progression in two independent cohorts. Circulating GDF-15 may be a marker for intrarenal GDF15-related signaling pathways associated with CKD and CKD progression.
Multiple variants in 5q31.1 are associated with systemic lupus erythematosus susceptibility and subphenotypes in the Han Chinese population
Authors: L.L. Wen, Z.W. Zhu, C. Yang, L. Liu, X.B. Zuo, D.L. Morris, J.F. Dou, L. Ye, Y.Y. Cheng, H.M. Guo, H.Q. Huang, Y. Lin, C.H. Zhu, L.L. Tang, M.Y. Chen, Y. Zhou, Y.T. Ding, B. Liang, F.S. Zhou, J.P. Gao, X.F. Tang, X.D. Zheng, W.J. Wang, X.Y. Yin, H.Y. Tang, L.D. Sun, S. Yang, X.J. Zhang, Y.J. Sheng, Y. Cui
Journal: British Journal of Dermatology (2017)

A previous study provided evidence for a genetic association between PPP2CA on 5q31.1 and systemic lupus erythematosus (SLE) across multi‐ancestral cohorts, but failed to find significant evidence for an association in the Han Chinese population. To explore the association between this locus and SLE using data from our previously published genome‐wide association study (GWAS). Single‐nucleotide polymorphisms (SNPs) rs7726414 and rs244689 (near TCF7 and PPP2CA in 5q31.1) were selected as candidate independent associations from a large‐scale study in a Han Chinese population consisting of 1047 cases and 1205 controls. Subsequently, 3509 cases and 8246 controls were genotyped in two further replication studies. We then investigated the SNPs' associations with SLE subphenotypes and gene expression in peripheral blood mononuclear cells. Highly significant associations with SLE in the Han Chinese population were detected for SNPs rs7726414 and rs244689 by combining the genotype data from our previous GWAS and two independent replication cohorts. Further conditional analyses indicated that these two SNPs contribute to disease susceptibility independently. A significant association with SLE, age at diagnosis < 20 years, was found for rs7726414 (P = 0·001). The expression levels of TCF7 and PPP2CA messenger RNA in patients with SLE were significantly decreased compared with those in healthy controls. This study found evidence for multiple associations with SLE in 5q31.1 at genome‐wide levels of significance for the first time in a Han Chinese population, in a combined genotype dataset. These findings suggest that variants in the 5q31.1 locus not only provide novel insights into the genetic architecture of SLE, but also contribute to the complex subphenotypes of SLE.
The Incidence, Risk Factors, and Prognosis of Recurrent Venous Thromboembolism (VTE) in Patients with Advanced Solid Cancers Receiving Anticoagulation Therapy After the Diagnosis of Index Vte; A Korean Venous Thromboembolism Registry Study.
Authors: Ho-Young Yhim, Moon Ju Jang, Won-Il Choi, Yong Cheol Lee, Jeong-Ok Lee, Keun-Wook Lee, Soo-Mee Bang, Sung Hyun Kim, Yeo-Kyeoung Kim, Hye Jung Chang, Jae-Yong Kwak, Chang-Yeol Yim
Journal: Blood (2012)
A phase II study of atorvastatin and celecoxib in patients with rising PSA following local therapy for prostate cancer (PC).
Authors: Susan Goodin, Mark N. Stein, Weichung Shih, Shou-En Lu, Xi Zheng, Monica Anand, Chandrika Jeyamohan, Tina M. Mayer, Robert A. Somer, Elisabeth Heath, Allan Conney, Robert S. DiPaola
Journal: Journal of Clinical Oncology (2012)

89 Background: Single agent atorvastatin and celecoxib have been associated with reductions in the risk of PC. Our laboratories have demonstrated that low doses of the drug combination have synergistic effects inhibiting the progression of LNCaP tumors to androgen independence. We therefore sought to determine the effects of the combination in androgen-dependent PC on PSA kinetics and the plasma correlates of IL-6, C-reactive protein (CRP), PGE-2, and the pharmacokinetics of the drug combination to validate preclinical biomarker findings. Methods: Patients with rising PSA after primary therapy for PC were enrolled. Patient must have three rising PSA values, each obtained at least 1 month apart. No prior hormone-ablative therapy was allowed, except in the neoadjuvant setting or in the setting of salvage XRT completed 3 months prior to enrollment. Patients with any history of coronary artery disease or a previous myocardial infarction in the past 6 months were excluded. All patients were treated with atorvastatin 20 mg daily and celecoxib 200 mg twice a day for 6 months. Paired pre-treatment and on treatment PSA kinetics were compared using the Wilcoxon Signed Rank test. Results: We report on 14 patients that have completed therapy. Median pretreatment PSA slope was 0.14 log PSA/mo (median PSADT 4.98 mos), in contrast to the median on treatment slope of 0.09 log PSA/mo (median PSADT 7.37 mos); p=0.11. Eleven of the fourteen patients completed the 6 months of therapy, 1 patient withdrew and 2 patients therapy was stopped early due to lack of response. A declining PSA was observed in one patient. The combination was well tolerated, with no clinically significant therapy related toxicities ( &gt; grade 1) reported in 76 months of therapy. Conclusions: In this ongoing phase II trial, the combination of low dose atorvastatin and celecoxib has been well tolerated and demonstrates a tendency of increasing PSA doubling time. Enrollment continues with analysis of IL-6, CRP, and PGE-2 to be correlated to individual clinical results.
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Authors: Takeru Asano, Yusuke Meguri, Takanori Yoshioka, Yuriko Kishi, Miki Iwamoto, Makoto Nakamura, Yasuhisa Sando, Hideo Yagita, John Koreth, Haesook T. Kim, Edwin P. Alyea, Philippe Armand, Corey S. Cutler, Vincent T. Ho, Joseph H. Antin, Robert J. Soiffer, Yoshinobu Maeda, Mitsune Tanimoto, Jerome Ritz, Ken-ichi Matsuoka
Journal: Blood (2017)
Are there “local hotspots?” When concepts of cognitive psychology do not fit with physiological results
Authors: Quentin Gaucher, Jean-Marc Edeline
Journal: Behavioral and Brain Sciences (2016)

Abstract Mather and colleagues' arguments require rethinking at the mechanistic level. The arguments on the physiological effects of norepinephrine at the cortical level are inconsistent with large parts of the literature. There is no evidence that norepinephrine induces local “hotspots”: Norepinephrine mainly decreases evoked responses; facilitating effects are rare and not localized. More generally, the idea that perception benefits from “local hotspots” is hardly compatible with the fact that neural representations involve largely distributed activation of cortical and subcortical networks.
The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.
Authors: Karl J. Aichberger, Matthias Mayerhofer, Karoline V. Gleixner, Maria-Theresa Krauth, Alexander Gruze, Winfried F. Pickl, Volker Wacheck, Edgar Selzer, Christian Sillaber, Peter Valent
Journal: Blood (2006)
Selective Inhibition of the proteasome's β2 Catalytic Subunit Alone Does Not Induce Cytotoxicity, but Resensitizes Bortezomib-Refractory Myeloma Cells for Bortezomib Treatment
Authors: Marianne Kraus, Bobby Florea, Jürgen Bader, Nan Li, Paul Geurink, Wouter van der Linden, Hermen S Overkleeft, Christoph Driessen
Journal: Blood (2011)
Data Selection Importance in the Study of the Association Between Maternal Smoking During Pregnancy and Schizophrenia: Response to Meier et al.
Authors: Solja Niemelä, Andre Sourander, Heljä-Marja Surcel, Susanna Hinkka-Yli-Salomäki, Ian W. McKeague, Keely Cheslack-Postava, Alan S. Brown
Journal: American Journal of Psychiatry (2017)
Constitutive Activation of SHP2 Protein Tyrosine Phosphatase Cooperates with HoxA10 Overexpression for Progression to Acute Myeloid Leukemia in a Murine Model
Authors: Hao Wang, Stephan Lindsey, Iwona Konieczna, Elizabeth Horvath, Ling Bei, Weiqi Huang, Elizabeth A. Eklund
Journal: Blood (2008)
Brexit plan has few details on securing health workers from abroad
Authors: Anne Gulland
Journal: BMJ (2017)

In its long awaited white paper on leaving the European Union the UK government has said it wants to create an immigration system that will encourage the “brightest and best” to come to the country.

The paper, which has been criticised for being short on detail, emphasises that the UK will always want “high-skilled immigration,” offering some reassurance to people concerned about the UK’s reliance on doctors from the European Union. The paper also emphasises the “important contribution” made to UK …
Rational for the Use of a Targeted-Therapy Using ABT-737 In Mantle-Cell Lymphoma
Authors: Cyrille Touzeau, Christelle Dousset, Lynda Bodet, Stephanie Bonnaud, Patricia Gomez-Bougie, Thomas Gastinne, Soraya Wuilleme, Anne Moreau, Philippe Moreau, Catherine Pellat-Deceunynck, Martine Amiot, Steven Le Gouill
Journal: Blood (2010)
Magic-TT (Magnetism-induced cell target transplantation) Enhanced the CD45+ Cells Target Migration, in Situ Proliferation and Promotion of Hematopoietic Recovery after Transplantation
Authors: Qianli Jiang, Hao Huang, Yongjun Zhou, Qiuxia Zhang, Sun Xiaowei, Minchun Zhang, Yanyan Ye, Zhihao Zheng, Jiapeng Wang, Li Liu, Jerry Kitbok Majaw, Jing Sun, Qifa Liu
Journal: Blood (2015)
Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma.
Authors: David Ilson, Karyn A. Goodman, Yelena Yuriy Janjigian, Manish A. Shah, David Paul Kelsen, Nabil P. Rizk, Valerie W. Rusch, Abraham Jing-Ching Wu, Jenny Campbell, Marinela Capanu, Manjit S. Bains
Journal: Journal of Clinical Oncology (2012)

4061 Background: Preop chemo and radiotherapy (RT) with weekly irinotecan (I), cisplatin (C) and 5040 cGy is tolerable and active [Cancer, in press]. Bevacizumab (B) + weekly I/C in advanced esophagogastric cancer increased response rate and PFS without an increase in toxicity [JCO 24: 5201; 2006]. In a phase II trial in esophageal adenocarcinoma (EA) we combed B + I/C with RT as preop therapy. A toxicity analysis after 10 patients (pts) undergoing surgery indicated no unexpected toxicity with B [JCO 27: Abstract 4573; 2009], and we completed a planned accrual of 33 pts. Methods: Pts had resectable distal esophageal or Siewert’s I or II EA, T2-3 or N1 staged by EUS, PET, and CT scan. Induction chemo: I: 50-65 mg/m 2 + C: 30 mg/m 2 weeks 1,2,4,5, B: 7.5 mg/kg weeks 1 and 4; Chemort: 180 cGy daily fractions to 5040 cGy, I/C weeks 7,8,10,11+ B weeks 7,10. Esophagectomy was planned 6-8 weeks after RT. Postop: B: 7.5 mg/kg every 3 weeks for 8 cycles. Results: 33 pts were enrolled. 26 male: 7 female; distal esophagus 11 (33%), GEJ 22 (67%); 21 T3N1 (64%); 10 T3N0 (30%); 2 T2N0-1 (6%). 25/33 pts went to surgery (76%), 24 had R0 resection (73%). Pathologic CR 5 pts (15%). 8 pts did not going to surgery: 2 for adverse events (9%, 1 CVA due to patent foramen ovale, 1 esophageal perforation due to endoscopic biopsy), 6 for progressive disease (18%). 21/24 pts (88%) received adjuvant B, 20 (95%) completed all cycles. Grade 3/4 toxicity in 30 evaluable pts during chemort: 24% neutropenia, 3% neutropenic fever, 23% esophagitis, 13% dehydration, 13% thrombocytopenia, 7% pulmonary embolism, 3% nausea/vomiting. Surgical complications: 3 anastomotic leaks (12%), 4 respiratory failure (16%), 1 pulmonary embolism (4%), 2 post op deaths (8%). At a median follow up of 20 months, PFS was 14 months and OS was 30 months. Conclusions: The addition of B to preop chemoRT in EA was tolerable without increase in treatment toxicity or surgical complications. There was no suggestion of improved pathologic CR, PFS, or OS with the addition of B to I/C/RT. Evaluation of B in phase III trials of chemort does not appear warranted. Supported by a grant from Genentech.
Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial.
Authors: Josep-Maria Ribera, Albert Oriol, Mireia Morgades, Josep Sarra, Pau Montesinos, Salut Brunet, Ramon Guardia, Pascual Fernández-Abellan, Teresa Bernal, Arancha Bermudez, Maria-Jose Moreno, Ricardo Parody, Mar Tormo, Eloy Del Potro, Andreu Llorente, Raimundo Garcia-Boyero, Jordi Esteve, Maria-Jose Rabuñal, Emilia Pardal, Carlos Grande, Javier Bueno, Antonia Cladera, Concepcion Bethencourt, Victoria Martin-Reina, Maria-Luz Amigo, Jesus-Maria Hernandez-Rivas, Miguel-Angel Sanz, Evarist Feliu
Journal: Blood (2008)
Allogeneic Stem Cell Transplantation (SCT) in Advanced Chronic Myeloid Leukemia (CML) Patients after Tyrosine Kinase Inhibitor (TKI) Therapy
Authors: Philipp D. le Coutre, Philipp Hemmati, Stefan Neuburger, Theis Terwey, Gero Massenkeil, Peter Daniel, Bernd Dörken, Renate Arnold
Journal: Blood (2008)
Defunding Planned Parenthood—The Stakes for America’s Women
Authors: Chloe Ciccariello
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A Plasmonic Coupling Substrate Based on Sandwich Structure of Ultrathin Silica‐Coated Silver Nanocubes and Flower‐Like Alumina‐Coated Etched Aluminum for Sensitive Detection of Biomarkers in Urine
Authors: Minh‐Kha Nguyen, Wei‐Nien Su, Bing‐Joe Hwang
Journal: Advanced Healthcare Materials (2017)

Interactions between substrate and plasmonic nanostructures can give rise to unique optical properties and influence performance in plasmonic biosensing applications. In this study, a substrate with low refractive index and roughness based on flower-like alumina-coated etched aluminum foil (f-Al2 O3 /e-Al) has been fabricated. Silver@silica (Ag@SiO2 ) nanocubes (NCs) assemble in an edge-edge configuration when deposited on this substrate. The rough surface texture of f-Al2 O3 /e-Al provides a pathway for coupling of incident light to surface plasmons. The Ag@SiO2 /f-Al2 O3 /e-Al substrate exhibits a coupling efficiency of laser light sources into surface plasmon hotspots for both surface-enhanced Raman scattering (SERS) and metal-enhanced photoluminescence (MEPL). Moreover, the shelf life of this substrate is significantly improved due to a reduction in oxygen diffusion rate mediated by the ultrathin silica spacer and the flower-like Al2 O3 dielectric layer. Creatinine and flavin adenine dinucleotide are biomolecules present in human blood and urine. With advanced label-free SERS and MEPL techniques, it is possible to detect these biomarkers in urine, allowing cheap, noninvasive, yet sensitive analysis. The approach explored in this work can be developed into a powerful encoding tool for high-throughput bioanalysis.
Carving nature at its joints or cutting its effective loops? On the dangers of trying to disentangle intertwined mental processes
Authors: Robert L. Goldstone, Joshua R. de Leeuw, David H. Landy
Journal: Behavioral and Brain Sciences (2016)

Abstract Attention is often inextricably intertwined with perception, and it is deployed not only to spatial regions, but also to sensory dimensions, learned dimensions, and learned complex configurations. Firestone &amp; Scholl's (F&amp;S)'s tactic of isolating visual perceptual processes from attention and action has the negative consequence of neglecting interactions that are critically important for allowing people to perceive their world in efficient and useful ways.
Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000).
Authors: L. Ades, E. Raffoux, S. Chevret, S. de Botton, A. Guerci, A. Pigneux, A.M. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, T. Pabst, S. Meyer-Monard, F. Maloisel, E. Deconinck, D. Caillot, N. Gratecos, J.J. Sotto, A. Ferrant, P. Turlure, X. Thomas, N. Fegueux, P. Brault, O. Reman, P. Chevallier, P. Travade, V. Leblond, G. Leverger, A. Stamatoullas, C. Pautas, B. Beve, C. Chomienne, H. Dombret, L. Degos, P. Fenaux
Journal: Blood (2004)
Increased Free Heme Levels and Red Blood Cell Transfusions Are Associated with Thrombosis in Neonates and Infants Undergoing Cardiac Surgery for Congenital Heart Disease
Authors: Moritz Stolla, Kelly Henrichs, Jill M. Cholette, Anthony Pietropaoli, Richard P. Phipps, Sherry Spinelli, Neil Blumberg
Journal: Blood (2014)
Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin’s Lymphoma (NHL): Analysis of SWOG Clinical Trials.
Authors: Julia Schaefer-Cutillo, Vaseem Chengazi, Derick R Peterson, David G. Maloney, Kevin Kibler, Erin Cebula, Steven Bernstein, Faith Young, Oliver W. Press, Lisa M. Rimsza, Richard I. Fisher, Jonathan W. Friedberg
Journal: Blood (2008)
Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea
Authors: Reginald V. Fant, Jack E. Henningfield, Brooks D. Cash, Leonard S. Dove, Paul S. Covington
Journal: Clinical Gastroenterology and Hepatology (2017)

Eluxadoline is approved by the Food and Drug Administration for the treatment of adults with irritable bowel syndrome with diarrhea (IBS-D). Eluxadoline is a locally acting mixed μ-opiod and κ-opioid receptor agonist and δ-opioid receptor antagonist. The abuse potential of eluxadoline was evaluated as part of the Phase 2 and 3 clinical trials assessing the efficacy, safety, and tolerability of the drug.One Phase 2 (IBS-2001) and two Phase 3 (IBS-3001 and IBS-3002) randomized controlled trials enrolled patients meeting Rome III criteria for IBS-D. Patients received oral twice-daily double-blind treatment with eluxadoline or placebo for 12, 26, or 52 weeks. The primary end point of these studies was the proportion of patients who had a composite response of decrease in abdominal pain and improvement in stool consistency on the same day for at least 50% of days. Safety data were pooled, and specific adverse event terms potentially related to abuse were assessed descriptively. Adverse events reported during a 2-week post-treatment period (IBS-3001) and a 4-week single-blind washout period (IBS-3002) were assessed for signs of opioid withdrawal. Potential withdrawal effects were assessed by using the Subjective Opiate Withdrawal Scale.Overall, 807 and 1032 patients received 1 or more doses of eluxadoline (75 or 100 mg, respectively), and 975 patients received placebo. The overall incidence of adverse events potentially related to abuse did not differ significantly among the groups given placebo, eluxadoline 75 mg, or eluxadoline 100 mg (2.8%, 2.7%, and 4.3%, respectively). The most common adverse events potentially related to abuse were anxiety and somnolence, which occurred in less than 2% of patients in each group. Median overall Subjective Opiate Withdrawal Scale scores did not differ significantly among the groups given placebo, eluxadoline 75 mg, or eluxadoline 100 mg (3.0, 2.0, and 3.0, respectively).In an analysis of data from Phase 2 and Phase 3 trials of eluxadoline (75 or 100 mg) for patients with IBS-D, data revealed no signs of abuse potential for eluxadoline. ClinicalTrials.gov numbers: NCT01130272, NCT01553591, NCT01553747.
Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies
Authors: Leon Bernal-Mizrachi, Ajay K Nooka, Chandra Pooja, Monica S Chatwal, Sungjin Kim, Zhengjia Chen, Jeanne Kowalski, Jonathan L. Kaufman, Sagar Lonial
Journal: Blood (2014)
Nuclear receptors: emerging drug targets for parasitic diseases
Authors: Zhu Wang, Nathaniel E. Schaffer, Steven A. Kliewer, David J. Mangelsdorf
Journal: Journal of Clinical Investigation (2017)

Parasitic worms infect billions of people worldwide. Current treatments rely on a small group of drugs that have been used for decades. A shortcoming of these drugs is their inability to target the intractable infectious stage of the parasite. As well-known therapeutic targets in mammals, nuclear receptors have begun to be studied in parasitic worms, where they are widely distributed and play key roles in governing metabolic and developmental transcriptional networks. One such nuclear receptor is DAF-12, which is required for normal nematode development, including the all-important infectious stage. Here we review the emerging literature that implicates DAF-12 and potentially other nuclear receptors as novel anthelmintic targets.